Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
BJU Int ; 134(1): 110-118, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38587276

RESUMEN

OBJECTIVE: To report the protocol of a study evaluating the efficacy of transdermal oestradiol (E2) gel in reducing the adverse effects of androgen deprivation therapy (ADT), specifically on sexual function, and to assess the utility of E2 in combination with supervised exercise. STUDY DESIGN AND METHODS: The primary endpoint of this open-label Phase IIA randomized controlled trial is the efficacy of transdermal E2 gel. Secondary endpoints include: (i) the occurrence of ADT-induced adverse effects; (ii) the safety and tolerability of E2; (iii) the impact of E2 with or without exercise on physical, physiological, muscle, and systemic biomarkers; and (iv) quality of life. The trial will recruit high-risk PCa patients (n = 310) undergoing external beam radiation therapy with adjuvant subcutaneous ADT. Participants will be stratified and randomized in a 1:1 ratio to either the E2 + ADT arm or the ADT-only control arm. Additionally, a subset of patients (n = 120) will be randomized into a supervised exercise programme. RESULTS: The primary outcome is assessed according to the efficacy of E2 in mitigating the deterioration of Expanded Prostate Cancer Index Composite sexual function domain scores. Secondary outcomes are assessed according to the occurrence of ADT-induced adverse effects, safety and tolerability of E2, impact of E2 with or without exercise on physical performance, body composition, bone mineral density, muscle size, systematic biomarkers, and quality of life. CONCLUSION: The ESTRACISE study's innovative design can offer novel insights about the benefits of E2 gel, and the substudy can reinforce the benefits resistance training and deliver valuable new novel insights into the synergistic benefits of E2 gel and exercise, which are currently unknown. TRIAL REGISTRATION: The protocol has been registered in euclinicaltrials.eu (2023-504704-28-00) and in clinicaltrials.gov (NCT06271551).


Asunto(s)
Administración Cutánea , Antagonistas de Andrógenos , Estradiol , Terapia por Ejercicio , Neoplasias de la Próstata , Humanos , Masculino , Antagonistas de Andrógenos/efectos adversos , Antagonistas de Andrógenos/uso terapéutico , Ensayos Clínicos Fase II como Asunto , Terapia Combinada , Estradiol/administración & dosificación , Terapia por Ejercicio/métodos , Neoplasias de la Próstata/tratamiento farmacológico , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto
2.
Ophthalmic Epidemiol ; 27(2): 121-131, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31830848

RESUMEN

Purpose: To describe the epidemiology of Microbial Keratitis (MK) in Uganda.Methods: We prospectively recruited patients presenting with MK at two main eye units in Southern Uganda between December 2016 and March 2018. We collected information on clinical history and presentation, microbiology and 3-month outcomes. Poor vision was defined as vision < 6/60).Results: 313 individuals were enrolled. Median age was 47 years (range 18-96) and 174 (56%) were male. Median presentation time was 17 days from onset (IQR 8-32). Trauma was reported by 29% and use of Traditional Eye Medicine by 60%. Majority presented with severe infections (median infiltrate size 5.2 mm); 47% were blind in the affected eye (vision < 3/60). Microbiology was available from 270 cases: 62% were fungal, 7% mixed (bacterial and fungal), 7% bacterial and 24% no organism detected. At 3 months, 30% of the participants were blind in the affected eye, while 9% had lost their eye from the infection. Delayed presentation (overall p = .007) and prior use of Traditional Eye Medicine (aOR 1.58 [95% CI 1.04-2.42], p = .033) were responsible for poor presentation. Predictors of poor vision at 3 months were: baseline vision (aOR 2.98 [95%CI 2.12-4.19], p < .0001), infiltrate size (aOR 1.19 [95%CI 1.03-1.36], p < .020) and perforation at presentation (aOR 9.93 [95% CI 3.70-26.6], p < .0001).Conclusion: The most important outcome predictor was the state of the eye at presentation, facilitated by prior use of Traditional Eye Medicine and delayed presentation. In order to improve outcomes, we need effective early interventions.


Asunto(s)
Queratitis/epidemiología , Queratitis/microbiología , Trastornos de la Visión/diagnóstico , Trastornos de la Visión/etiología , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Ceguera/epidemiología , Ceguera/etiología , Estudios de Cohortes , Córnea/microbiología , Córnea/patología , Úlcera de la Córnea/microbiología , Úlcera de la Córnea/patología , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Infecciones Bacterianas del Ojo/epidemiología , Infecciones Bacterianas del Ojo/microbiología , Infecciones Fúngicas del Ojo/tratamiento farmacológico , Infecciones Fúngicas del Ojo/epidemiología , Infecciones Fúngicas del Ojo/microbiología , Femenino , Humanos , Queratitis/complicaciones , Queratitis/tratamiento farmacológico , Masculino , Medicinas Tradicionales Africanas/efectos adversos , Medicinas Tradicionales Africanas/métodos , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Resultado del Tratamiento , Uganda/epidemiología , Trastornos de la Visión/epidemiología , Agudeza Visual/fisiología
3.
J Fam Health Care ; 20(2): 42-4, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20518369

RESUMEN

Genetics is an important contributory factor in many medical conditions. Having an understanding of the genetic basis of diseases can therefore be helpful in identifying and supporting people who have, or are at risk of having, a genetic condition. Most of the current practical applications relate to conditions which are known to have a definite mode of inheritance (for instance cystic fibrosis or familial hypercholesterolaemia) or which are due to chromosomal anomalies (such as Down syndrome). Current research projects are attempting to identify and understand the genetic factors associated with common diseases (such as diabetes and Crohn's disease) but it will be some time before these are likely to be useful clinically. Key skills in the delivery of a holistic family practice service include being able to collect a genetic family history, identifying people at risk and knowing how to refer to specialist services.


Asunto(s)
Enfermedades Genéticas Congénitas/prevención & control , Anamnesis , Derivación y Consulta , Neoplasias Colorrectales Hereditarias sin Poliposis/prevención & control , Enfermería de la Familia , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Osteogénesis Imperfecta/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA